share_log

四環醫藥：自願公告-四環醫藥獨家代理的雙波射頻治療儀Sylfirm X獲國家藥監局頒發三類醫療器械註冊證

SIHUAN PHARM: VOLUNTARY ANNOUNCEMENT-SIHUAN PHARMACEUTICAL OBTAINED CLASS III MEDICAL DEVICE REGISTRATION CERTIFICATE FROM NMPA FOR EXCLUSIVELY DISTRIBUTED DUAL WAVE RF TREATMENT DEVICE SYLFIRM X

香港交易所 ·  Mar 25 00:00
Summary by Moomoo AI
四環醫藥控股集團有限公司宣布，其獨家代理的雙波射頻治療儀Sylfirm X已於2024年3月19日獲得中國國家藥品監督管理局頒發的三類醫療器械註冊證。Sylfirm X是全球首個同時獲得美國FDA和中國國家藥監局批准的雙波射頻治療儀，專門用於皮膚治療，包括減輕皺紋和治療痤瘡疤痕。該產品具有創新的雙波射頻脈衝技術和微針電極，能夠精准治療皮膚真皮全層，並已證明無嚴重不良反應，術後恢復期短。四環醫藥的醫美子公司渼顏空間於2022年1月10日與韓國維奧達成獨家代理協議，獲得Sylfirm X在中國大陸、香港及澳門的獨家代理權。四環醫藥在醫美領域的佈局顯示其對中國醫美市場的長期承諾和發展潛力。
四環醫藥控股集團有限公司宣布，其獨家代理的雙波射頻治療儀Sylfirm X已於2024年3月19日獲得中國國家藥品監督管理局頒發的三類醫療器械註冊證。Sylfirm X是全球首個同時獲得美國FDA和中國國家藥監局批准的雙波射頻治療儀，專門用於皮膚治療，包括減輕皺紋和治療痤瘡疤痕。該產品具有創新的雙波射頻脈衝技術和微針電極，能夠精准治療皮膚真皮全層，並已證明無嚴重不良反應，術後恢復期短。四環醫藥的醫美子公司渼顏空間於2022年1月10日與韓國維奧達成獨家代理協議，獲得Sylfirm X在中國大陸、香港及澳門的獨家代理權。四環醫藥在醫美領域的佈局顯示其對中國醫美市場的長期承諾和發展潛力。
Four Ring Pharmaceutical Holdings Group Limited announced that Sylfirm X, its exclusive agent, the dual-wave frequency therapeutic instrument Sylfirm X has been granted a three-class medical device registration certificate issued by the National Drug Administration of China on March 19, 2024. Sylfirm X is the world's first dual-wave RF therapy device to be approved simultaneously by the US FDA and the Chinese National Drug Administration, specifically for skin treatments, including wrinkle reduction and acne scars. Featuring innovative dual-wave RF pulse technology and micro-needle electrodes, the product is able to accurately treat the entire dermis layer of the skin and is proven to have no serious adverse reactions and a short postoperative recovery period. On January 10, 2022, the...Show More
Four Ring Pharmaceutical Holdings Group Limited announced that Sylfirm X, its exclusive agent, the dual-wave frequency therapeutic instrument Sylfirm X has been granted a three-class medical device registration certificate issued by the National Drug Administration of China on March 19, 2024. Sylfirm X is the world's first dual-wave RF therapy device to be approved simultaneously by the US FDA and the Chinese National Drug Administration, specifically for skin treatments, including wrinkle reduction and acne scars. Featuring innovative dual-wave RF pulse technology and micro-needle electrodes, the product is able to accurately treat the entire dermis layer of the skin and is proven to have no serious adverse reactions and a short postoperative recovery period. On January 10, 2022, the medical and cosmetic subsidiary of Four Ring Pharmaceuticals reached an exclusive agency agreement with Viao of Korea to acquire Sylfirm X exclusive agency rights in Mainland China, Hong Kong and Macau. The layout of Quadruple Pharmaceuticals in the field of medical beauty shows its long-term commitment and development potential to the Chinese medical beauty market.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more